Ionis Pharmaceuticals Inc... (IONS)
Ionis Pharmaceuticals Statistics
Share Statistics
Ionis Pharmaceuticals has 157.90M shares outstanding. The number of shares has increased by 8.33% in one year.
| Shares Outstanding | 157.90M |
| Shares Change (YoY) | 8.33% |
| Shares Change (QoQ) | 0.12% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 153.47M |
| Failed to Deliver (FTD) Shares | 891 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 10.24M, so 6.49% of the outstanding shares have been sold short.
| Short Interest | 10.24M |
| Short % of Shares Out | 6.49% |
| Short % of Float | 7.04% |
| Short Ratio (days to cover) | 6.49 |
Valuation Ratios
The PE ratio is -11.52 and the forward PE ratio is -12.36. Ionis Pharmaceuticals 's PEG ratio is -0.61.
| PE Ratio | -11.52 |
| Forward PE | -12.36 |
| PS Ratio | 7.41 |
| Forward PS | 3 |
| PB Ratio | 8.88 |
| P/FCF Ratio | -9.57 |
| PEG Ratio | -0.61 |
Enterprise Valuation
Ionis Pharmaceuticals Inc. has an Enterprise Value (EV) of 8.30B.
| EV / Earnings | -18.28 |
| EV / Sales | 11.77 |
| EV / EBITDA | -17.47 |
| EV / EBIT | -17.47 |
| EV / FCF | -15.19 |
Financial Position
The company has a current ratio of 8.47, with a Debt / Equity ratio of 2.39.
| Current Ratio | 8.47 |
| Quick Ratio | 8.43 |
| Debt / Equity | 2.39 |
| Total Debt / Capitalization | 70.52 |
| Cash Flow / Debt | -0.36 |
| Interest Coverage | 27.96 |
Financial Efficiency
Return on equity (ROE) is -0.77% and return on capital (ROIC) is -24.13%.
| Return on Equity (ROE) | -0.77% |
| Return on Assets (ROA) | -0.15% |
| Return on Capital (ROIC) | -24.13% |
| Revenue Per Employee | 760.67K |
| Profits Per Employee | -489.64K |
| Employee Count | 927 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 0.9 |
Taxes
| Income Tax | 6.17M |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -24.88% in the last 52 weeks. The beta is 0.35, so Ionis Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.35 |
| 52-Week Price Change | -24.88% |
| 50-Day Moving Average | 34.25 |
| 200-Day Moving Average | 40.18 |
| Relative Strength Index (RSI) | 45.37 |
| Average Volume (20 Days) | 1.61M |
Income Statement
In the last 12 months, Ionis Pharmaceuticals had revenue of 705.14M and earned -453.90M in profits. Earnings per share was -3.04.
| Revenue | 705.14M |
| Gross Profit | 693.92M |
| Operating Income | -475.08M |
| Net Income | -453.90M |
| EBITDA | -475.08M |
| EBIT | -475.08M |
| Earnings Per Share (EPS) | -3.04 |
Balance Sheet
The company has 242.08M in cash and 1.41B in debt, giving a net cash position of -1.17B.
| Cash & Cash Equivalents | 242.08M |
| Total Debt | 1.41B |
| Net Cash | -1.17B |
| Retained Earnings | -2.25B |
| Total Assets | 3.08B |
| Working Capital | 2.41B |
Cash Flow
In the last 12 months, operating cash flow was -500.95M and capital expenditures -45.28M, giving a free cash flow of -546.23M.
| Operating Cash Flow | -500.95M |
| Capital Expenditures | -45.28M |
| Free Cash Flow | -546.23M |
| FCF Per Share | -3.65 |
Margins
Gross margin is 98.41%, with operating and profit margins of -67.37% and -64.37%.
| Gross Margin | 98.41% |
| Operating Margin | -67.37% |
| Pretax Margin | -65.25% |
| Profit Margin | -64.37% |
| EBITDA Margin | -67.37% |
| EBIT Margin | -67.37% |
| FCF Margin | -77.46% |
Dividends & Yields
IONS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -9.3% |
| FCF Yield | -10.58% |
Analyst Forecast
The average price target for IONS is $62, which is 89.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $62 |
| Price Target Difference | 89.6% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
Scores
| Altman Z-Score | 1.16 |
| Piotroski F-Score | 5 |